The administration of BCR and CDK4/6 inhibitors ibrutinib and palbociclib has a favorable impact on the survival of mice transplanted with the CLL murine cells carrying the CDKN2A, CDKN2B, and TP53 lesions (87). The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.